

# Christoph Neumann-Haefelin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1125473/publications.pdf>

Version: 2024-02-01

108  
papers

5,439  
citations

94381

37  
h-index

91828

69  
g-index

121  
all docs

121  
docs citations

121  
times ranked

7019  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis E virus and Bell's palsy. <i>European Journal of Neurology</i> , 2022, 29, 820-825.	1.7	7
2	Immunopathology caused by impaired CD8 <sup>+</sup> T cell responses. <i>European Journal of Immunology</i> , 2022, 52, 1390-1395.	1.6	3
3	Adaptive Immune Responses, Immune Escape and Immune-Mediated Pathogenesis during HDV Infection. <i>Viruses</i> , 2022, 14, 198.	1.5	9
4	Immune-mediated Hepatitis associated with SARS-CoV-2 mRNA vaccination. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.2	1
5	SARS-CoV-2-specific adaptive immune response after mRNA vaccination in liver transplanted patients. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.2	0
6	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 397-409.	1.8	59
7	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	2.6	10
8	Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency. <i>Journal of Clinical Immunology</i> , 2022, 42, 253-265.	2.0	19
9	SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. <i>Journal of Hepatology</i> , 2022, 77, 653-659.	1.8	67
10	SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals. <i>Nature Microbiology</i> , 2022, 7, 675-679.	5.9	29
11	Another important step toward a prophylactic vaccine against hepatitis C. <i>Hepatology</i> , 2022, 76, 917-919.	3.6	1
12	Mechanisms of CD8 <sup>+</sup> T-cell failure in chronic hepatitis E virus infection. <i>Journal of Hepatology</i> , 2022, 77, 978-990.	1.8	15
13	TOX defines the degree of CD8 <sup>+</sup> T cell dysfunction in distinct phases of chronic HBV infection. <i>Gut</i> , 2021, 70, 1550-1560.	6.1	46
14	Characterization of pre-existing and induced SARS-CoV-2-specific CD8 <sup>+</sup> T cells. <i>Nature Medicine</i> , 2021, 27, 78-85.	15.2	295
15	IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 649-660.	1.8	20
16	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1b Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	2.4	12
17	Memory-like HCV-specific CD8 <sup>+</sup> T cells retain a molecular scar after cure of chronic HCV infection. <i>Nature Immunology</i> , 2021, 22, 229-239.	7.0	95
18	Acute CNS infections – Expanding the spectrum of neurological manifestations of hepatitis E virus?. <i>Journal of the Neurological Sciences</i> , 2021, 423, 117387.	0.3	7

#	ARTICLE	IF	CITATIONS
19	Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. <i>Gut</i> , 2021, 70, 1782-1794.	6.1	125
20	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. <i>Journal of Hepatology</i> , 2021, 74, 1362-1372.	1.8	74
21	Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. <i>Immunity</i> , 2021, 54, 1594-1610.e11.	6.6	210
22	Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. <i>Nature</i> , 2021, 597, 268-273.	13.7	279
23	Hepatitis E virus as a trigger for Guillain-Barré syndrome. <i>BMC Neurology</i> , 2021, 21, 304.	0.8	5
24	Human hepatitis D virus-specific T cell epitopes. <i>JHEP Reports</i> , 2021, 3, 100294.	2.6	3
25	Mutational escape from cellular immunity in viral hepatitis: variations on a theme. <i>Current Opinion in Virology</i> , 2021, 50, 110-118.	2.6	12
26	Immunotherapy and therapeutic vaccines for chronic HBV infection. <i>Current Opinion in Virology</i> , 2021, 51, 149-157.	2.6	14
27	Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. <i>Nature Communications</i> , 2021, 12, 6405.	5.8	128
28	Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination. <i>Nature Communications</i> , 2021, 12, 6720.	5.8	33
29	Adaptive Immune Response against Hepatitis C Virus. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5644.	1.8	18
30	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. <i>Liver International</i> , 2020, 40, 2660-2671.	1.9	2
31	Follicular T helper cells shape the HCV-specific CD4+ T cell repertoire after virus elimination. <i>Journal of Clinical Investigation</i> , 2020, 130, 998-1009.	3.9	39
32	PS-028-Viral escape contributes to the failure of hepatitis D virus-specific CD8+ T-cells and drives evolution of HDV. <i>Journal of Hepatology</i> , 2019, 70, e21.	1.8	0
33	PS-032-Impact of antigen recognition on memory-like HCV-specific CD8+ T-cells. <i>Journal of Hepatology</i> , 2019, 70, e22-e23.	1.8	0
34	Chronic hepatitis E after kidney transplantation with an antibody response suggestive of reinfection: a case report. <i>BMC Infectious Diseases</i> , 2019, 19, 675.	1.3	7
35	Heterogeneity of HBV-Specific CD8+ T-Cell Failure: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2240.	2.2	31
36	SAT-381-TAA-specific CD8+ T-cell responses are inefficiently induced in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e802-e803.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Paving the way for T cell-based immunotherapies in chronic hepatitis E. <i>Journal of Hepatology</i> , 2019, 71, 648-650.	1.8	4
38	FRI-138-HBVcore-versus HBVpolymerase-specific CD8+ T cells differ in chronically HBV-infected patients. <i>Journal of Hepatology</i> , 2019, 70, e448.	1.8	0
39	FRI-154-Augmentation of HBV-specific CD4 T cell responses via combined OX40 stimulation and PD-L1 blockade. <i>Journal of Hepatology</i> , 2019, 70, e456.	1.8	0
40	FRI-150-Association of the immunodominant HLA-B35:01 restricted CD8+ T cell epitope with clustered viral evolution in HBV polymerase. <i>Journal of Hepatology</i> , 2019, 70, e454.	1.8	0
41	PS-179-Analysis of long-term persistence of HCV resistance-associated substitutions within NS, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure. <i>Journal of Hepatology</i> , 2019, 70, e111.	1.8	3
42	OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection. <i>Journal of Hepatology</i> , 2019, 70, 1103-1113.	1.8	57
43	Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level. <i>Gastroenterology</i> , 2019, 156, 1820-1833.	0.6	44
44	ERAP1 allotypes shape the epitope repertoire of virus-specific CD8+ T cell responses in acute hepatitis C virus infection. <i>Journal of Hepatology</i> , 2019, 70, 1072-1081.	1.8	15
45	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. <i>Liver Cancer</i> , 2019, 8, 281-294.	4.2	31
46	Immunological cure of HBV infection. <i>Hepatology International</i> , 2019, 13, 113-124.	1.9	38
47	Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. <i>Gut</i> , 2019, 68, 905-915.	6.1	122
48	NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 70, 351-360.	1.8	32
49	Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma. <i>Oncotarget</i> , 2019, 10, 5194-5206.	0.8	16
50	Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8 <sup>+</sup> T Cells. <i>Journal of Virology</i> , 2018, 92, .	1.5	23
51	Differential virus-specific CD8 <sup>+</sup> T cell epitope repertoire in hepatitis C virus genotype 1 versus 4. <i>Journal of Viral Hepatitis</i> , 2018, 25, 779-790.	1.0	7
52	Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll-Like Receptor 3 in Hepatocytes. <i>Gastroenterology</i> , 2018, 154, 2237-2251.e16.	0.6	63
53	HCV-Specific T Cell Responses During and After Chronic HCV Infection. <i>Viruses</i> , 2018, 10, 645.	1.5	40
54	Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>Hepatology Communications</i> , 2018, 2, 1051-1063.	2.0	12

#	ARTICLE	IF	CITATIONS
55	Entering the spotlight: hepatitis B surface antigen-specific B cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 4257-4259.	3.9	13
56	TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation. <i>Nature Communications</i> , 2017, 8, 15050.	5.8	185
57	Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. <i>Nature Microbiology</i> , 2017, 2, 16247.	5.9	52
58	Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. <i>BMC Gastroenterology</i> , 2017, 17, 98.	0.8	18
59	Coffee consumption protects against progression in liver cirrhosis and increases long-term survival after liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1470-1475.	1.4	9
60	Sigmoid Colon Compression Due to Liver Migration and Hypertrophy. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, A27.	2.4	0
61	The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8+ T cell activation. <i>Journal of Hepatology</i> , 2016, 64, 1305-1314.	1.8	3
62	CD8+ T-Cell Responses in Hepatitis B and C: The (HLA-) A, B, and C of Hepatitis B and C. <i>Digestive Diseases</i> , 2016, 34, 396-409.	0.8	34
63	Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development. <i>Virus Evolution</i> , 2016, 2, vew024.	2.2	17
64	Virus-Specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-Helper Cells in Patients With Acute and Chronic HCV Infections. <i>Gastroenterology</i> , 2016, 150, 696-706.e3.	0.6	62
65	Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus. <i>Wellcome Open Research</i> , 2016, 1, 9.	0.9	23
66	Tetramer Enrichment Reveals the Presence of Phenotypically Diverse Hepatitis C Virus-Specific CD8 <sup>+</sup> T Cells in Chronic Infection. <i>Journal of Virology</i> , 2015, 89, 25-34.	1.5	20
67	An uncommon presentation of a common pathogen. <i>Gut</i> , 2015, 64, 1411-1411.	6.1	1
68	Association of serum zinc levels with liver function and survival in patients awaiting liver transplantation. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 805-811.	0.8	7
69	Importance of molecular typing in confirmation of the source of a national hepatitis A virus outbreak in Norway and the detection of a related cluster in Germany. <i>Archives of Virology</i> , 2015, 160, 2823-2826.	0.9	6
70	Prediction of clinical outcome in advanced hepatitis C-associated liver disease: identification of patients at the highest need for antiviral treatment and surveillance. <i>Gut</i> , 2015, 64, 193-194.	6.1	1
71	PNPLA3 in end-stage liver disease: Alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1477-1484.	1.4	39
72	Immunodominance and functional alterations of tumor-associated antigen-specific CD8 <sup>+</sup> T-cell responses in hepatocellular carcinoma. <i>Hepatology</i> , 2014, 59, 1415-1426.	3.6	290

#	ARTICLE	IF	CITATIONS
73	HLA-B*27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope. <i>Journal of Hepatology</i> , 2014, 60, 22-29.	1.8	24
74	Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. <i>Journal of Hepatology</i> , 2014, 61, 538-543.	1.8	218
75	Susceptibility to chronic hepatitis C virus infection is influenced by sequence differences in immunodominant CD8+ T cell epitopes. <i>Journal of Hepatology</i> , 2013, 58, 24-30.	1.8	16
76	Adaptive Immune Responses in Hepatitis C Virus Infection. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 243-262.	0.7	55
77	HLA-B27-mediated protection in HIV and hepatitis C virus infection and pathogenesis in spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 426-433.	2.0	39
78	Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection. <i>Hepatology</i> , 2013, 58, 881-889.	3.6	19
79	Rapid Antigen Processing and Presentation of a Protective and Immunodominant HLA-B*27-restricted Hepatitis C Virus-specific CD8+ T-cell Epitope. <i>PLoS Pathogens</i> , 2012, 8, e1003042.	2.1	25
80	Cellular Immune Responses to Hepatocellular Carcinoma: Lessons for Immunotherapy. <i>Digestive Diseases</i> , 2012, 30, 483-491.	0.8	36
81	Differential Antigen Specificity of Hepatitis C Virus-Specific Interleukin 17 <sup>+</sup> and Interferon $\gamma$ -Producing CD8+ T Cells During Chronic Infection. <i>Journal of Infectious Diseases</i> , 2012, 205, 1142-1146.	1.9	15
82	Inhibitory Molecules That Regulate Expansion and Restoration of HCV-Specific CD4+ T Cells in Patients With Chronic Infection. <i>Gastroenterology</i> , 2011, 141, 1422-1431.e6.	0.6	72
83	Host genetics in immune-mediated hepatitis C virus clearance. <i>Biomarkers in Medicine</i> , 2011, 5, 155-169.	0.6	17
84	CD8+ T-Cell Response Promotes Evolution of Hepatitis C Virus Nonstructural Proteins. <i>Gastroenterology</i> , 2011, 140, 2064-2073.	0.6	42
85	Success and Failure of Virus-Specific T Cell Responses in Hepatitis C Virus Infection. <i>Digestive Diseases</i> , 2011, 29, 416-422.	0.8	27
86	Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations. <i>Hepatology</i> , 2011, 54, 1157-1166.	3.6	47
87	Lack of <i>ex vivo</i> peripheral and intrahepatic $\alpha$ -fetoprotein-specific CD4+ responses in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2011, 129, 2171-2182.	2.3	18
88	Compensatory Mutations Restore the Replication Defects Caused by Cytotoxic T Lymphocyte Escape Mutations in Hepatitis C Virus Polymerase. <i>Journal of Virology</i> , 2011, 85, 11883-11890.	1.5	30
89	Immunodominance of HLA-A2-Restricted Hepatitis C Virus-Specific CD8 <sup>+</sup> T Cell Responses Is Linked to Naïve-Precursor Frequency. <i>Journal of Virology</i> , 2011, 85, 5232-5236.	1.5	51
90	Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. <i>Hepatology</i> , 2010, 51, 54-62.	3.6	48

#	ARTICLE	IF	CITATIONS
91	Hepatitis C virus recombinants are rare even among intravenous drug users. <i>Journal of Medical Virology</i> , 2010, 82, 232-238.	2.5	25
92	Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability. <i>Journal of Hepatology</i> , 2009, 50, 693-704.	1.8	7
93	Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. <i>Journal of Clinical Investigation</i> , 2009, 119, 376-86.	3.9	99
94	Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. <i>Hepatology</i> , 2008, 47, 1824-1836.	3.6	108
95	Comprehensive analysis of the Î±-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2008, 48, 1821-1833.	3.6	60
96	Scavenger Receptor Class B Is Required for Hepatitis C Virus Uptake and Cross-Presentation by Human Dendritic Cells. <i>Journal of Virology</i> , 2008, 82, 3466-3479.	1.5	79
97	Escape from HLA-B*08-Restricted CD8 T Cells by Hepatitis C Virus Is Associated with Fitness Costs. <i>Journal of Virology</i> , 2008, 82, 11803-11812.	1.5	45
98	Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. <i>Biological Chemistry</i> , 2008, 389, 457-67.	1.2	37
99	Analysis of the Evolutionary Forces in an Immunodominant CD8 Epitope in Hepatitis C Virus at a Population Level. <i>Journal of Virology</i> , 2008, 82, 3438-3451.	1.5	58
100	Absence of viral escape within a frequently recognized HLA-A26-restricted CD8+ T-cell epitope targeting the functionally constrained hepatitis C virus NS5A/5B cleavage site. <i>Journal of General Virology</i> , 2007, 88, 1986-1991.	1.3	21
101	Analysis of CD127 and KLRG1 Expression on Hepatitis C Virus-Specific CD8 + T Cells Reveals the Existence of Different Memory T-Cell Subsets in the Peripheral Blood and Liver. <i>Journal of Virology</i> , 2007, 81, 945-953.	1.5	102
102	CD4+ T cells don't always help. <i>Blood</i> , 2007, 110, 1408-1409.	0.6	0
103	Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2007, 13, 4839.	1.4	46
104	Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. <i>Hepatology</i> , 2006, 43, 563-572.	3.6	191
105	Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. <i>Blood</i> , 2005, 105, 3605-3614.	0.6	86
106	Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. <i>Hepatology</i> , 2005, 42, 828-837.	3.6	140
107	T Cells with a CD4 + CD25 + Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8 + T Cells during Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2005, 79, 7860-7867.	1.5	386
108	In Vitro Studies with Purified Components Reveal Signal Recognition Particle (SRP) and SecA/SecB as Constituents of Two Independent Protein-targeting Pathways of <i>Escherichia coli</i> . <i>Molecular Biology of the Cell</i> , 1999, 10, 2163-2173.	0.9	149